I can understand a minor correction due to market sentiment but a 7% fall in a pharma stock like Biocon on the day of railway budget with which it has no correlation is strange. Either the correction is silly or the upmove itself in Biocon was not based on any fundamentals.
4.33 PM Jul 8th
the outcome of the Delhi High Court case brought by Roche against Biocon and Mylan in February gains significance. Roche has alleged that Biocon/Mylan has misrepresented its drugs as a biosimilar of its bestselling breast cancer drug, Trastuzumab (Herceptin), without having undergone the required
10.04 AM Jul 8th
Follow moneycontrol.comFacebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window Windows 8
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.